Managing Gout in Primary Care
Evolving Strategies for Diagnosis and Long-Term Management
Meeting Slides
Clinical Tools
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.
Khanna D, et al. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446.
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.
Khanna D, et al. Arthritis Care Res (Hoboken). 2012;64(10):1447-1461.
Evolution of management of gout: a comparison of recent guidelines
Khanna PP, FitzGerald J. Curr Opin Rheumatol. 2015;27(2):139-146.
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Neogi T, Jansen TL, Dalbeth N, et al. Ann Rheum Dis. 2015;74(10):1789-1798
Educational Materials for Patients and Their Families
What Is Gout? Fast Facts: An Easy-to-Read Series of Publications for the Public
A brochure in simplified language from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health
Gout
Patient brochure from the American Colllege of Rheumatology
Gout Education for Patients
Patient information from the Gout & Uric Acid Education Society
Suggested Readings
The Emerging Role of Biotechnological Drugs in the Treatment of Gout.
Cavagna L, Taylor WJ. BioMed Res Int. 2014. doi: 10.1155/2014/264859. Epub 2014 Apr 16.
Imaging in gout: a review of the recent developments.
Chowalloor PV, et al. Ther Adv Musculoskelet Dis. 2014;6(4):131-143.
New medications in development for the treatment of hyperuricemia of gout.
Diaz-Torné C, et al. Curr Opin Rheumatol. 2015;27(2):164-169.
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Fleischmann R, et al. Rheumatology. 2014;53(12):2167-2174.
The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality.
Gustafsson D, Unwin R. BMC Nephrology. 2013;14:164.
Emerging therapies for gout.
Edwards NL, So A. Rheum Dis Clin North Am. 2014;40(2):375-387.
The association of gout with socioeconomic status in primary care: a cross-sectional observational study.
Hayward RA, et al. Rheumatology (Oxford). 2013;52(11):2004-2008.
The crystallization of monosodium urate.
Martillo MA, et al. Curr Rheumatol Rep. 2014;16(2):400. doi:10.1007/s11926-013-0400-9.
Racial and gender disparities in patients with gout.
Singh JA. Curr Rheumatol Rep. 2013;15(2):307. doi:10.1007/s11926-012-0307-x.
Gout and its comorbidities: implications for therapy.
Stamp LK, Chapman PT. Rheumatology (Oxford). 2013;52(1):34-44.
Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
Strand V, et al. J Rheumatol. 2012;39(7):1450-1457.
Recent advances in management of gout.
Suresh E, Das P. QJM. 2012;105(5):407-417.
Interactive PresentationClinical Updates on the Management of Gout
Michael H. Pillinger, MD
Updates on Diagnosis and Evidence-Based Management
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
Targeting Immune Dysregulation and Delivering Comprehensive Care
The PCP’s Role in Timely Recognition and Referral
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Debates & Discussions on the Evolving Role of JAK Inhibitors
Improving Patient Outcomes Through Shared Clinical Decision Making
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
From Patient Evaluations to New Targeted Therapies
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
New Avenues to Improve Patient Outcomes
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies
